Latest Insights - page 66 | BiopharmaTrend

DeepCure Unveils AI-Driven Chemical Synthesis Platform

DeepCure, a company specializing in AI-driven therapeutic discovery, has introduced a development in chemical synthesis with its Inspired Chemistry™ platform. This technology aims to address the limitations of manual chemical …

Continue ›››

Owkin Expands Oncology Pipeline with AI and EP2/EP4 Dual Inhibitor from Idorsia

Owkin, a pioneering TechBio company leveraging advanced causal* AI for precision drug discovery, has announced a significant expansion of its drug pipeline in oncology and immunology. This development follows a …

Continue ›››

Tempus AI Files S-1 Registration to Go Public

Tempus AI has officially filed its S-1 registration statement with the Securities and Exchange Commission (SEC), marking a significant step toward becoming a publicly traded company. This move not only …

Continue ›››

Sanofi, Formation Bio, and OpenAI Partner to Innovate Drug Development with AI

Sanofi, Formation Bio, and OpenAI have announced a pioneering collaboration aimed at accelerating drug development using artificial intelligence (AI). This partnership will combine proprietary data, advanced software, and specialized AI …

Continue ›››

LabGenius Secures £35 Million to Enhance ML-Driven Antibody Discovery

LabGenius, a leading drug discovery company leveraging machine learning (ML) to discover novel therapeutic antibodies, has successfully completed a £35 million Series B financing round. This latest investment brings the …

Continue ›››

Insilico Medicine Unveils nach0: A Comprehensive LLM for Chemical and Biomedical Applications

Insilico Medicine, a clinical-stage AI-driven drug discovery company, in collaboration with NVIDIA, has introduced nach0, a novel large language model (LLM) transformer designed for biological and chemical tasks. Detailed in …

Continue ›››

AstraZeneca to Establish $1.5 Billion ADC Manufacturing Facility in Singapore

AstraZeneca has announced plans to construct a $1.5 billion manufacturing facility in Singapore dedicated to producing antibody-drug conjugates (ADCs), a promising class of cancer therapies. This will be the pharmaceutical …

Continue ›››

Accenture's Investment in Turbine Enhances AI-Powered Cell Simulations for Biopharma R&D

Accenture has strategically invested in Turbine, a company specializing in predictive simulation with a platform aimed at interpreting human biology. This investment, managed through Accenture Ventures, is set to expand …

Continue ›››

Insilico Medicine Initiates Phase I Clinical Trial for Novel QPCTL Inhibitor

Insilico Medicine, a biotechnology company specializing in generative artificial intelligence, has begun dosing patients in the first clinical trial for ISM8207, a small molecule inhibitor targeting QPCTL. This drug candidate, …

Continue ›››

Veranova and Phorum.AI Partner to Deliver Generative AI Chemistry Optimization to the Pharmaceutical & Biotech Industry

Veranova and Phorum.AI have partnered to revolutionize pharmaceutical manufacturing processes using generative artificial intelligence. This collaboration combines Veranova's extensive 20-year dataset with Phorum.AI's cutting-edge AI technology to develop optimized manufacturing …

Continue ›››

Karius Gains $100M and FDA Breakthrough Designation for Genomic Pneumonia Test

Karius Inc., a leading company in genomic diagnostics for infectious diseases, announced that its Karius Test has received the FDA's Breakthrough Device designation. This designation aims to facilitate the development …

Continue ›››

Sartorius and NVIDIA to Develop AI Models for Stem Cell-Derived Organoids, Reducing Animal Testing in Drug Discovery

Sartorius, a leader in life sciences and bioprocessing, is expanding its collaboration with NVIDIA to enhance the development of innovative therapies. A key focus of this collaboration is the development …

Continue ›››